Assessment of progranulin in egyptian type 2 diabetic patients as a novel biomarker for diabetic nephropathy
Paper Details
Assessment of progranulin in egyptian type 2 diabetic patients as a novel biomarker for diabetic nephropathy
Abstract
Progranulin (PGRN) is a cysteine rich secreted protein, expressed in epithelial cells, immune cells, neurons, and adipocytes. The present study aimed to determine serum progranulin level in Egyptian type 2 diabetic patients and the association between its level with diabetic and renal biomarkers to evaluate it as a predictor marker of diabetic nephropathy. This study included 60 subjects classified as: 20 normal control, 20 diabetic patients with normal kidney function (DM) and 20 diabetic patients with nephropathy (DN). Concentrations of serum PGRN, Cystatin-C and IL-6 were analyzed by enzyme linked immune sorbent assay (ELISA). Diabetic and renal biomarkers were measured in all subjects. Serum levels of PGRN were markedly higher in type 2 diabetic patients with significantly higher values detectable in clinical diabetic nephropathy. The elevations ins-PGRN parallel the degree of hyperglycemia, hyperinsulinemia, and insulin resistance in type 2 diabetic patients. Renal biomarkers a slight significant change in DM group, this change was augmented in DN group. Cystatin-C and IL-6 were slightly increased in DM group while, e-GFR was non-significantly changed. In DN group, the increase in serum Cystatin-C and IL-6 were highly significant, while e-GFR was dramatically decreased. Our results suggest that PGRN may be considered as a highly sensitive and specific biomarker for diabetic nephropathy.
Bi Y, Wang T, Xu M, Xu Y, Li M, Lu J. 2012. Advanced research on risk factors of type 2 diabetes. Diabetes Metabolism Research Review 28, 32–9.
Chih-Hung L, Yi-Cheng C, Lee-Ming C. 2016. Early detection of diabetic kidney disease: Present limitations and future perspectives. World Journal of Diabetes7, 290-301.
Doumas BT, Watson WA, Biggs HG. 1972 Standard methods of clinical chemistry. New York: Academic Press 7, 175.
Eriksenand J, Mackenzie I. 2008. “Progranulin: normal function and role in neurodegeneration, ”Journal of Neurochemistry. 104, 287–297.
Flier JS, Kahn CR, Roth J. 1997. The New England Journal of Medicine 300, 413–9.
Gregg E, Li Y, Wang J, Burrows N, Ali M, Rolka D, Williams D, Geiss L. 2014. Changes in diabetes-related complications in the United States, 1990-2010. The New England Journal of Medicine. 370, 1514-1523.
Grey V, Perlas M, Aebi C. 1996. Immunoturbidimetric method for determination of hemoglobin A1c. Clinical Chemistry 42, 2046–7.
He Z, Bateman A. 2003. Progranulin (granulin-epithelin precursor, PC-cellderived growth factor, acrogranin) mediates tissue repair and tumorigenesis.Journal of Moleculer Medicine (Berl). 81, 600–12.
International Diabetes Federation. 2015.IDF Diabetes Atlas, 7th ed. Brussels, Belgium: International Diabetes Federation.
Jaffe MZ. 1886. Determination of creatinine. Physiologycal. Chemistry 10, 391-7.
Jerums G, Panagiotopoulos S, Premaratne E, Power DA, MacIsaac RJ. 2008. Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis. American Journal of Nephrology 28, 614–627.
Judit R, Denise F, Thomas E, Peter K, Anette B, Ulrike L. 2013 Serum Levels of the adipokine progranulin depend on renal function. Pathophysiology /Complications, Diabetes Care 36.
Kakadiya J, Haresh M, Nehal S. 2010. Protective effect of hesperidin on cardiovascular complication in experimentally induced myocardial infarction in diabetes in rats. Journal of Biological Clinical Pharmacology 1, 85-91.
Kojima Y, Ono K, Inoue K. 2009.Progranulin expression in advanced human atherosclerotic plaque. Atherosclerosis 206, 102–108.
Kramer C, Leitão C, Pinto L, Silveiro S, Gross J, Canani L. 2007. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 30, 1998-2000.
Li H, Zhou B, Xu L, Liu J, Zang W, Wu S. 2014. Circulating PGRN is significantly associated with systemic insulin sensitivity and autophagic activity in metabolic syndrome. Endocrinology 155, 3493–507.
Lin X, Zhou B, Huixia L, Jiali L, Junhui D, Weijin Z, Shufang W, Hongzhi S. 2015. Serum levels of progranulin are closely associated with microvascular complication in type 2 diabetes. Disease Markers. 1-9.
Liu CJ, Bosch X. 2012. Progranulin: a growth factor, a novel TNFR ligand and a drug target. Pharmacology Therapy. 133, 124–32.
Lu Y, Zheng L, Zhang W, Feng T, Liu J, Wang X. 2014.Growth factor progranulin contributes to cervical cancer cell proliferation and transformation in vivo and in vitro. Gynecological Oncology. 134, 364–71.
Mann J, Schmieder R, McQueen M. 2008. ONTARGET Investigators. Renal out comes with telmisartan, ramipril, orboth, in people at high vascular risk (theONTARGET study): a multicenter, randomized, doubleblind, controlled trial. Lancet 372, 547–553.
Matsubara T, Mita A, Minami K. 2012. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metabolism. 15, 38–50.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28, 412–9.
Mauer M, Zinman B, Gardiner R. 2009. Renal and retinal effects of enalapril and losartan in type 1 diabetes. The New England Journal of medicine 361, 40–51.
Moon E, Lee S, Kang T, Kim H, Choi S, Son M, Kim S. 2014. Dioscorea Extract (DA-9801) Modulates Markers of Peripheral Neuropathy in Type 2 Diabetic db/db Mice. Biomolecule Therapy 22, 445-452.
Okura H, Yamashita S, Ohama T, Saga A, Yamamoto-Kakuta A. 2010.HDL/apolipoprotein A-I binds to macrophage-derived progranulin and suppresses its conversion into pro-inflammatory granulins. Journal of Atherosclerosis 17, 568-577.
Qu H, Deng H, Hu Z. 2013. Plasma progranulin concentrations are increased in patients with type 2 diabetes and obesity and correlated with insulin resistance. Mediators Inflammation.3013, 1-6.
Richter J, Focke D, Ebert T. 2013. Serum levels of the adipokine progranulin depend on renal function. Diabetes Care. 36, 410–414.
Shi H, Tzameli I, Bjørbæk C, Flier J. 2004. “Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulinsignaling,”Journal of Biological Chemistry.279, 34733–34740.
Steinke J, Mauer M. 2008. International Diabetic Nephropathy Study Group. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patient. Pediatric Endocrinology Review. 5, 958–963.
Toenjes A, Fasshauer M, Kratzsch J, Stumvoll M, Blueher M. 2010. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 5, 13911.
Trinder P. 1969. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Analytical Clinical Biochemistry 6, 24–7.
Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley Connell AT, Molitch ME. 2014. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 37, 2864-2883.
Uslu S, Efe B, Alataş O, Kebapçi N, Colak O, Demirüstü C, Yörük A. 2005.Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. Journal of Nephrology 18, 559-67.
Yatzidis HL. 1987. Determination of serum total protein. Journal of Clinical Chemistry 23, 908.
Ying C, Zhuying L, Fuxing Z, Hang Z, Qian Y, Hua L, Jiyuan S, Siwang W. 2016. Evaluating pharmacological effects of two major components of shuangdan oral liquid: Role of danshensu and paeonol in diabetic nephropathy rat. Biomolecule Therapy 24, 536-542.
Youn B, Bang S, Kl¨oting N. 2009. “Serum progranulin concentrations may be associated with macrophage infiltration into omental adipose tissue,” Diabetes 58, 627– 636.
Yun K, Mi R, Jung E, Ji Young M, Sang H, Sang S, Bo H, Soo H, Yong K, In J. 2011. Cystatin C as an Early Biomarker of Nephropathy in Patients with Type 2 Diabetes. Journal of Korean Medical Science 26, 258-263.
Zimmet P, Alberti KG, Shaw J. 2001. Global and societal implications of the diabetes epidemic. Nature 414, 782–787.
Magda Kamal Ezz, Eman M. Abd El Azeem (2016), Assessment of progranulin in egyptian type 2 diabetic patients as a novel biomarker for diabetic nephropathy; IJB, V9, N6, December, P350-359
https://innspub.net/assessment-of-progranulin-in-egyptian-type-2-diabetic-patients-as-a-novel-biomarker-for-diabetic-nephropathy/
Copyright © 2016
By Authors and International
Network for Natural Sciences
(INNSPUB) https://innspub.net
This article is published under the terms of the
Creative Commons Attribution License 4.0